Trial Profile
Complement Regulation to Undo Systemic Harm in Preeclampsia: The CRUSH Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Nov 2023
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Preeclampsia
- Focus Therapeutic Use
- Acronyms CRUSH
- 10 Nov 2023 Status changed from suspended to discontinued.
- 16 Jun 2022 Status changed from recruiting to suspended.
- 13 Sep 2021 Planned End Date changed from 1 Aug 2023 to 13 Mar 2024.